DK1601697T3 - Oprensning af antistof ved protein A- og ionbytningskromatografi - Google Patents

Oprensning af antistof ved protein A- og ionbytningskromatografi

Info

Publication number
DK1601697T3
DK1601697T3 DK04715906T DK04715906T DK1601697T3 DK 1601697 T3 DK1601697 T3 DK 1601697T3 DK 04715906 T DK04715906 T DK 04715906T DK 04715906 T DK04715906 T DK 04715906T DK 1601697 T3 DK1601697 T3 DK 1601697T3
Authority
DK
Denmark
Prior art keywords
antibody
purification
protein
ion exchange
exchange chromatography
Prior art date
Application number
DK04715906T
Other languages
English (en)
Inventor
Julian Bonnerjea
Anna Preneta
Original Assignee
Lonza Biologics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32929391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1601697(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0304576.2A external-priority patent/GB0304576D0/en
Application filed by Lonza Biologics Plc filed Critical Lonza Biologics Plc
Application granted granted Critical
Publication of DK1601697T3 publication Critical patent/DK1601697T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
DK04715906T 2003-02-28 2004-03-01 Oprensning af antistof ved protein A- og ionbytningskromatografi DK1601697T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0304576.2A GB0304576D0 (en) 2003-02-28 2003-02-28 Protein a chromatography
US46497303P 2003-04-24 2003-04-24
PCT/EP2004/002041 WO2004076485A1 (en) 2003-02-28 2004-03-01 Antibody purification by protein a and ion exchange chromatography

Publications (1)

Publication Number Publication Date
DK1601697T3 true DK1601697T3 (da) 2007-10-01

Family

ID=32929391

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04715906T DK1601697T3 (da) 2003-02-28 2004-03-01 Oprensning af antistof ved protein A- og ionbytningskromatografi

Country Status (6)

Country Link
EP (1) EP1601697B1 (da)
AU (1) AU2004215653B2 (da)
CA (1) CA2516518A1 (da)
DK (1) DK1601697T3 (da)
PT (1) PT1601697E (da)
WO (1) WO2004076485A1 (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516518A1 (en) 2003-02-28 2004-09-10 Lonza Biologics Plc. Antibody purification by protein a and ion exchange chromatography
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
DK3095793T3 (da) * 2003-07-28 2020-05-25 Genentech Inc Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
US20050165222A1 (en) * 2003-10-15 2005-07-28 Applera Corporation Method of reducing leachate from protein a affinity media
KR101221862B1 (ko) 2003-10-27 2013-01-14 와이어쓰 엘엘씨 하이드록시아파타이트 크로마토그래피를 사용한 고분자량응집체의 제거
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
SE0402558D0 (sv) * 2004-10-21 2004-10-21 Amersham Biosciences Ab A process for the purification of antibodies
CA2581208A1 (en) * 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
CA2583578C (en) * 2004-10-21 2014-04-01 Ge Healthcare Bio-Sciences Ab Chromatography ligand
AR054428A1 (es) * 2005-03-08 2007-06-27 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
CN1830495B (zh) * 2005-03-11 2010-12-15 广东天普生化医药股份有限公司 基于亲和吸附的血液净化方法及系统
EP1869065B1 (en) * 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
TWI320788B (en) 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
ZA200710330B (en) 2005-06-17 2009-12-30 Wyeth Corp Methods of purifying FC region containing proteins
AU2006296399B2 (en) 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
SI2061803T2 (sl) * 2006-08-28 2023-01-31 Ares Trading S.A. Postopek za čiščenje proteinov, ki vsebujejo FC
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
CN101679509A (zh) 2007-06-01 2010-03-24 弗·哈夫曼-拉罗切有限公司 免疫球蛋白纯化
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2281000A2 (en) * 2008-05-15 2011-02-09 Novo Nordisk A/S Antibody purification process
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8058407B2 (en) 2008-10-31 2011-11-15 Wyeth Llc Purification of acidic proteins using ceramic hydroxyapatite chromatography
JPWO2010071208A1 (ja) 2008-12-19 2012-05-31 武田薬品工業株式会社 抗体の精製方法
JP2012513425A (ja) 2008-12-22 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリンの精製
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
ES2813398T3 (es) 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
ES2982297T3 (es) 2009-12-18 2024-10-15 Novartis Ag Método de cromatografía de afinidad
EP2519536A4 (en) 2009-12-29 2013-06-05 Reddys Lab Ltd Dr PROTEIN PURIFICATION BY ION EXCHANGE
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR101574864B1 (ko) 2010-12-21 2015-12-11 에프. 호프만-라 로슈 아게 이소폼이 농축된 항체 제제 및 그의 제조 방법
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
SG186552A1 (en) 2011-06-08 2013-01-30 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
US9096648B2 (en) 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
SG11201402485UA (en) * 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN105051528A (zh) * 2012-11-15 2015-11-11 弗·哈夫曼-拉罗切有限公司 离子强度介导的pH梯度离子交换色谱
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2909139C (en) 2013-04-18 2021-07-06 Institut National De La Sante Et De La Recherche Medicale Composition with reduced immunogenicity
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
MX380658B (es) 2014-01-15 2025-03-11 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
PL3116891T3 (pl) 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
MX2016016318A (es) 2014-06-13 2017-06-12 Lupin Atlantis Holdings Sa Proceso para la purificacion de la proteina de fusion.
EP3207055A1 (en) 2014-10-15 2017-08-23 Xenothera Composition with reduced immunogenicity
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
WO2016103139A1 (en) * 2014-12-22 2016-06-30 Dr. Reddy's Laboratories Method for reduction of aggregates
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
CN113795515A (zh) 2019-04-30 2021-12-14 芝诺锡拉公司 用于治疗癌症的多克隆抗体和抗pd1或抗pdl1抗体的联合
EP4299756A4 (en) * 2021-03-09 2025-03-12 JCR Pharmaceuticals Co., Ltd. METHOD FOR PRODUCING AN ANTIBODY LYSOSOMALIC ENZYMFUSION PROTEIN
WO2023012321A1 (en) 2021-08-06 2023-02-09 Roche Diagnostics Gmbh Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084559A (en) * 1987-03-27 1992-01-28 Repligen Corporation Protein a domain mutants
US4983722A (en) * 1988-06-08 1991-01-08 Miles Inc. Removal of protein A from antibody preparations
JPH07155194A (ja) * 1993-12-10 1995-06-20 Teijin Ltd タンパク質の精製法
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
SE9503925D0 (sv) * 1995-11-07 1995-11-07 Pharmacia Biotech Ab Separationsmedium för IgG
CA2516518A1 (en) 2003-02-28 2004-09-10 Lonza Biologics Plc. Antibody purification by protein a and ion exchange chromatography

Also Published As

Publication number Publication date
PT1601697E (pt) 2007-09-04
WO2004076485A1 (en) 2004-09-10
EP1601697A1 (en) 2005-12-07
AU2004215653A1 (en) 2004-09-10
AU2004215653B2 (en) 2011-03-17
CA2516518A1 (en) 2004-09-10
EP1601697B1 (en) 2007-05-30

Similar Documents

Publication Publication Date Title
DK1601697T3 (da) Oprensning af antistof ved protein A- og ionbytningskromatografi
DK3095793T3 (da) Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
DK1615955T3 (da) Ændring af FCRN-bindingsaffiniteter eller serumhalveringstider af antistoffer ved mutagenese
DK1543038T4 (da) Proteinoprensning
HUE053833T2 (hu) Bispecifikus ellenanyag funkcionális proteinek helyettesítésére
DK1599504T3 (da) Modificeret antistof
DK1406656T3 (da) Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
DK1587542T3 (da) Anvendelse af anti-CD100-antistoffer
ECSP066436A (es) Compuestos heterociclicos fusionados
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
DK1501856T3 (da) Anti-HER2 antistofvarianter
NO20044347L (no) Anti-alfavbeta6-antistoff
DK1545574T3 (da) Fremgangsmåde til rensning af polypeptider ved simuleret moving-bed-chromatografi
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
DK1647529T3 (da) Fremgangsmåde til oprensing af spildevand
CY2010016I1 (el) Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl)
DK1273592T3 (da) Fremgangsmåde til oprensning af interferonproteiner ved hjælp af kationbytningskromatografi
DK1800693T3 (da) Adjuvans-terapi ved anvendelse af anti-glypican 3 antistoffer
ATE500256T1 (de) Neue kondensierte pyrrolocarbazole
FI20010558L (fi) Kappaleiden paikannus
DE60220587D1 (de) Ionenaustauschermembran
DK1353923T3 (da) Forbedret fremgangsmåde til syntese af carbapenem
NO20054120D0 (no) Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav
DK1527690T3 (da) Fremgangsmåde til dearomatisering af valleprotein
EP1598368A4 (en) ANTI-PCI neutralizing ANTIBODY